CancerNetwork®· @CancerNetwrk · X·· 2026-04-21评分60
正文 · 原文
Tebentafusp yielded a favorable 5-year survival rate vs investigator’s choice of therapy in HLA-A*02:01-positive uveal melanoma.
Read for more on the phase 3 IMCgp100-202 study
https://
hubs.li/Q04cPY080
#melsm #Melanoma #AACR26
热度 0 · 0 赞 · 0 回复 · 0 转发
来源：CancerNetwork® · x.com